Meeting
2021 ASCO Annual Meeting
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
Authors
Mingfang Zhao
Department of the Second Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Mingfang Zhao , Tao Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
ChiCTR2000032649, China
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9130)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9130
Abstract #
TPS9130
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Platinum-free chemotherapy in the new era of immunotherapy: A phase II study of camrelizumab combined with apatinib and albumin paclitaxel in advanced non-squamous NSCLC (CAPAP-lung).
First Author: Lin Wu
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
First Author: Giuseppe Lo Russo